Abstract 1557P
Background
Appraisal of oncology products by the UK National Institute for Health and Care Excellence (NICE) pose unique challenges, such as single arm trials, immature survival, limited data on patient/carer burden, increasing uncertainties. Patient experience, which is an integral part of the NICE process, can help mitigate some of the uncertainties and provide additional information. We aimed to assess the role of patient input in NICE decision-making process in oncology appraisals compared to other disease areas.
Methods
Completed NICE technology appraisals published between 2021–2023 were identified. The final appraisal consultation documents (FADs) describing the decision and rationale were reviewed for patient input. The main characteristics of the appraisal (e.g., type, disease area, rarity, patient population, and final recommendation), areas of patient input (e.g. prognosis, unmet need, clinical outcomes, treatment pathway, equality considerations, patients’ quality-of-life (QoL), impact on family/caregivers, impact of side effects) and details of the input (e.g. quantitative/qualitative) were extracted. Results were analysed using summary statistics.
Results
Of the 158 FADs, 51% were in oncology. The proportion of FADs with positive recommendations and the proportion including patient input in the FADs were similar in oncology vs. overall (91% vs. 92% and 87% vs. 88% respectively). Areas where patient input was most frequently reported were again similar for oncology vs. all disease areas: QoL was the most commonly mentioned input (60% in both oncology and all appraisals), followed by unmet need (46% vs. 43% respectively). Clinical outcomes were mentioned in 38% of oncology FADs, slightly lower than all appraisals (42%). Carer burden was only mentioned in 11% of oncology FADs, slightly less than in overall FADs (14%). Only one oncology FAD mentioned collecting patient experience quantitatively. No clear difference in patient input was observed between oncology appraisals and appraisals in other disease areas.
Conclusions
In oncology, there are further opportunities to explore and incorporate patient experience into the decision-making in the NICE technology appraisals.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10